Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Congenital conditions

US agency reaffirms folic acid advice for women planning pregnancy

The US Preventive Services Task Force (USPSTF) has reaffirmed its 2009 advice that all women who are planning or capable of pregnancy should take a daily supplement of folic acid of between 0.4mg and 0.8mg (400–800µg) to reduce the risk of having a baby with neural tube defects.

The reaffirmed recommendation follows a review of the benefits of folic acid supplements based on the results of one randomised clinical trial, two cohort studies, eight case controlled studies and two publications since the 2009 advice was first published.

The USPSTF says that the risk to the mother and unborn child of taking the daily supplement is small and that there is “convincing evidence” that the supplement — which should be taken in the month before conception and the following three months of pregnancy — “provides substantial benefits” in reducing the risk of neural tube defects in the developing foetus.

Writing in JAMA[1] (online, 10 January 2017), the USPSTF says: “The USPSTF assessed the balance of the benefits and harms of folic acid supplementation in women of childbearing age and determined that the net benefit is substantial.

“Evidence is adequate that the harms to the mother or infant from folic acid supplementation taken at the usual doses are no greater than small.”

The USPSTF recommendation has an A status, which means that there is a high certainty that the net benefit is “substantial”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202174

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.